enVVeno Medical Corporation filed a definitive proxy statement on October 29, 2026, notifying stockholders of a virtual annual meeting scheduled for December 10, 2026, at 9:00 A.M. PST, with four items on the ballot.

Key Highlights

  • Annual meeting date: December 10, 2026 at 9:00 A.M. PST, conducted entirely as a virtual meeting via live webcast.
  • Record date: October 16, 2026 was set as the date for determining stockholders entitled to notice and voting rights.
  • Director election: Stockholders are asked to elect Robert C. Gray as a Class III Director to serve until the 2029 Annual Meeting.
  • New equity plan: Stockholders are asked to approve the adoption of the enVVeno Medical Corporation 2026 Equity Incentive Plan.
  • Auditor ratification: The Board recommends ratifying CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026.
  • Strategic pivot: According to the filing, the company redirected principal development efforts from VenoValve to enVVe following the FDA's not-approvable decision for VenoValve.
  • IDE approval: The company disclosed that in April it received FDA Investigational Device Exemption approval for the TAVVE pivotal study of the enVVe System.

enVVeno Medical's Proxy Agenda and enVVe Development Update

enVVeno Medical Corporation, a medical-device company focused on venous valve replacement therapies and listed on NASDAQ:NVNO, filed its definitive proxy statement on October 29, 2026. The filing presents four formal proposals for stockholder action at the December 10 virtual meeting. The Board of Directors unanimously recommends a vote "FOR" each of the four items: election of Class III Director Robert C. Gray, non-binding advisory approval of named executive officer compensation, ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2026, and adoption of the 2026 Equity Incentive Plan.

The proxy letter from Chief Executive Officer Robert A. Berman describes a significant shift in the company's development strategy. According to the filing, enVVeno Medical redirected its principal development efforts from VenoValve, a surgical replacement venous valve, to enVVe, described as a minimally invasive transcatheter replacement venous valve. The filing states that the FDA's not-approvable decision for VenoValve identified three principal concerns: bleeding from the surgical pocket following open surgery, insufficient hemodynamic evidence of effectiveness, and the potential for a Hawthorne or placebo effect. The enVVe System and the randomized TAVVE pivotal study were described as designed to address each of those concerns.

The filing discloses several operational milestones during the period covered. In April, the company received FDA IDE approval for the TAVVE pivotal study. In July, the company was issued its first U.S. patent covering the enVVe System, with additional patent applications pending both in the U.S. and internationally. In August, the company published a health economic study in the Journal of Vascular Surgery: Venous and Lymphatic Disorders, projecting healthcare savings from a replacement venous valve of approximately $32,000 over a five-year period compared to standard-of-care treatments. The company also noted that enVVe is designed for catheter-based delivery, potentially allowing interventional radiologists and interventional cardiologists, in addition to vascular surgeons, to perform the procedure.

What Was Disclosed

enVVeno Medical filed a definitive proxy statement on October 29, 2026, calling a December 10, 2026 virtual stockholder meeting with four proposals on the ballot, while also describing the company's strategic transition from VenoValve to the enVVe transcatheter venous valve system and the TAVVE pivotal study.